EOS884448

DRUG2 trials

Sponsors

iTeos Therapeutics

Conditions

Advanced CancerMultiple Myeloma

Phase 1

First-In-Human Study of EOS884448 in Participants with Advanced Cancers.

CompletedNCT04335253

iTeos TherapeuticsAdvanced Cancer

Start: 2020-02-18End: 2022-04-07Updated: 2024-09-19

Study of Novel Regimens in Relapsed or Refractory Multiple Myeloma

TerminatedNCT05289492

iTeos TherapeuticsMultiple Myeloma

Start: 2022-05-01End: 2023-11-29Updated: 2024-10-26

Related Papers

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

Natural killer cells and bone marrow mesenchymal stem cells: A dangerous liaison in multiple myeloma

Clinical and Translational Discovery2022-07-281 citations

Abstract CT118: Preliminary data from Phase I first-in-human study of EOS884448, a novel potent anti-TIGIT antibody, monotherapy shows favorable tolerability profile and early signsof clinical activity in immune-resistant advanced cancers

Cancer Research2021-07-017 citations